



28 December 2022

ISSUE OF SHARES

Vectus Biosystems Limited (ASX:VBS) (Vectus or the Company) advises that today it has issued 1,371,875 new fully paid ordinary shares in Vectus (Shares).

The Company allotted 871,875 Shares under its Share Purchase Plan (SPP) to 44 participating shareholders. Details of the SPP were announced to ASX on 23 November and 2 December 2022, and the offer closed on 19 December 2022. The issue was completed at a price of \$0.80 per Share and raised \$697,500.

Vectus also allotted 500,000 Shares upon the exercise of 500,000 options with an exercise price of \$0.50. The options were issued on 27 July 2020 and the funds of \$250,000 from the exercise were received prior to the expiry date of 24 December 2022.

The proceeds from the SPP and funds raised from the exercise of options will be used to accelerate the Phase Ib clinical trial for VB0004, which targets the prevention and reversal of fibrosis in the heart and kidneys. Proceeds will also be used to advance the Company's other emerging lead compounds and for working capital.

Appendix 2As for the issue of these Shares were lodged with ASX prior to this announcement.

Cleansing Notice Under Section 708A(5)(e)

Vectus advises that on 28 December 2022 the Company issued a total of 1,371,875 new fully paid ordinary shares, as set out above. Vectus also advises that:

- (1) this notice is being given within five business days after the day of the issue under section 708A(5)(e) of the Corporations Act 2001 (Cth);
- (2) the Company issued the securities without disclosure to investors under Part 6D.2 of the Corporations Act 2001;
- (3) as at the date of this notice, Vectus has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act 2001 as they apply to the Company; and
 - (b) section 674 of the Corporations Act 2001; and
- (4) except as may be set out in this notice, there is no other information that is excluded information as at the date of this notice that is required to be set out in this notice under section 708A(6)(e) of the Corporations Act 2001.

Vectus Biosystems Limited

Robert J Waring
Company Secretary

This announcement was authorised by the Company's Deputy Chairman and Company Secretary.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

3-11 Primrose Avenue, Rosebery, NSW 2018 Telephone: +61 2 9381 1000 Facsimile: +61 2 9662 1720

Website: www.vectusbiosystems.com.au